|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||21.28 - 21.74|
|52 Week Range||19.77 - 33.00|
|Beta (3Y Monthly)||0.76|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.86|
SAN DIEGO, Feb. 14, 2019 -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the 8th Annual SVB Leerink Global.
SAN DIEGO, Feb. 12, 2019 -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019.
NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Citron Research, the activist short-seller headed by Andrew Left, has dug up some nasty evidence against Ligand Pharmaceuticals Inc. (LGND). In a 23-page report, Citron accused the San Diego-based biopharmaceutical company of misleading investors, adding that its future revenue calculations are a "pipe dream." The short seller then slapped a $35 price target on the stock, implying 80% downside from the report’s publication date. After failing to successfully develop its own drugs, Ligand switched its business model to focus on collecting royalties and milestone payments from compounds and intellectual property that it licenses to other drug developers.
Retrophin, Inc. (RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2018 to be approximately $44 million. For the fiscal year 2018, the Company expects total net product sales of approximately $164 million. The Company also provided a general update on its development programs, including anticipated milestones for 2019.
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks reached 52-week highs Thursday. Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. ...
Retrophin, Inc. (RTRX) today announced the appointment of Eric Dube, Ph.D. as president and chief executive officer, effective January 4, 2019. Dr. Dube joins Retrophin from ViiV Healthcare, where he served as president of North America, and brings a successful track record of global leadership with significant expertise in delivering innovative therapies to address unmet patient needs.
SAN DIEGO, Jan. 02, 2019 -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare.
Retrophin, Inc. (RTRX) today announced that the first patient has been dosed in the PROTECT Study, a global, pivotal Phase 3 clinical trial evaluating the long-term nephroprotective potential of sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder that often leads to end-stage renal disease (ESRD). “With no approved therapies indicated for IgA nephropathy, dosing the first patient in the pivotal PROTECT Study brings us closer to our goal of ultimately delivering sparsentan as the first approved therapy for patients living with this rare disorder,” said Noah Rosenberg, M.D., chief medical officer of Retrophin. “The pivotal DUPLEX Study of sparsentan in FSGS is also underway, and the achievement of this latest milestone further underscores our commitment to investigating sparsentan’s potential as a first-in-class therapy for patients with rare kidney disorders.
Retrophin, Inc. (RTRX) today announced completion of patient enrollment in the pivotal Phase 3 FORT Study, which is evaluating the safety and efficacy of fosmetpantotenate for the treatment of pantothenate kinase-associated neurodegeneration (PKAN), a rare, progressive neurodegenerative genetic disorder. “Reaching this milestone brings us closer to potentially delivering fosmetpantotenate as the first disease-modifying therapy to patients with PKAN,” said Noah Rosenberg, M.D., chief medical officer of Retrophin. The Phase 3 FORT Study is an international, pivotal clinical trial designed to assess the safety and efficacy of fosmetpantotenate in approximately 82 patients with PKAN aged 6 to 65 years.
Is Retrophin Inc (NASDAQ:RTRX) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more resources than the average investor. The funds have access to […]
If you own shares in Retrophin Inc (NASDAQ:RTRX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of Read More...
SAN DIEGO, Nov. 28, 2018 -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the BMO 2018 Prescriptions for Success.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Retrophin (RTRX) delivered earnings and revenue surprises of -750.00% and -8.55%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had a loss of $1.34. Losses, adjusted for non-recurring costs and stock option expense, came to 68 cents per share. The drug developer posted revenue ...
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Retrophin, Inc. breached their fiduciary duties to shareholders.